161 related articles for article (PubMed ID: 36436128)
21. Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.
Kim J; Rajan SS; Du XL; Franzini L; Giordano SH; Morgan RO
Breast Cancer Res Treat; 2018 Jun; 169(3):573-586. PubMed ID: 29423900
[TBL] [Abstract][Full Text] [Related]
22. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
Uslu Y; Kocatepe V; Sezgin DS; Uras C
Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.
Friese CR; Pini TM; Li Y; Abrahamse PH; Graff JJ; Hamilton AS; Jagsi R; Janz NK; Hawley ST; Katz SJ; Griggs JJ
Breast Cancer Res Treat; 2013 Apr; 138(3):931-9. PubMed ID: 23542957
[TBL] [Abstract][Full Text] [Related]
24. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
[TBL] [Abstract][Full Text] [Related]
25. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
[TBL] [Abstract][Full Text] [Related]
26. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review.
Eliassen FM; Blåfjelldal V; Helland T; Hjorth CF; Hølland K; Lode L; Bertelsen BE; Janssen EAM; Mellgren G; Kvaløy JT; Søiland H; Lende TH
BMC Cancer; 2023 Jul; 23(1):625. PubMed ID: 37403065
[TBL] [Abstract][Full Text] [Related]
27. Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas.
Kim J; Kim MS; Rajan SS; Du XL; Franzini L; Kim TG; Giordano SH; Morgan RO
Curr Oncol; 2023 Mar; 30(4):3800-3816. PubMed ID: 37185401
[TBL] [Abstract][Full Text] [Related]
28. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
29. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors.
Raghavendra A; Sinha AK; Valle-Goffin J; Shen Y; Tripathy D; Barcenas CH
Clin Breast Cancer; 2018 Feb; 18(1):e7-e13. PubMed ID: 29239836
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant hormonal therapy use among insured, low-income women with breast cancer.
Kimmick G; Anderson R; Camacho F; Bhosle M; Hwang W; Balkrishnan R
J Clin Oncol; 2009 Jul; 27(21):3445-51. PubMed ID: 19451445
[TBL] [Abstract][Full Text] [Related]
31. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
32. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE
JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030
[TBL] [Abstract][Full Text] [Related]
33. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer.
Yung RL; Hassett MJ; Chen K; Gesten FC; Roohan PJ; Boscoe FP; Sinclair AH; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Jul; 104(14):1102-5. PubMed ID: 22773822
[TBL] [Abstract][Full Text] [Related]
34. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
[TBL] [Abstract][Full Text] [Related]
35. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
[TBL] [Abstract][Full Text] [Related]
36. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
[TBL] [Abstract][Full Text] [Related]
38. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
39. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors.
Sella T; Poorvu PD; Ruddy KJ; Gelber SI; Tamimi RM; Peppercorn JM; Schapira L; Borges VF; Come SE; Partridge AH; Rosenberg SM
Cancer; 2021 Aug; 127(16):2888-2894. PubMed ID: 33886123
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
